TransMedics Group, Inc. (TMDX) stock

TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/3029% below fair value

$91.38−0.62 (-0.67%)

Close on Nov 13, 2026Market cap $3.17BP/E 25.0Yield 0.00%

TransMedics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

TransMedics's EV/EBITDA was 23.2× on Nov 11, 2026, against 37.4× a year earlier. Over the last 2 years it ranged from 14.5× to 385.1×, with a median of 35.0×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	23.2×	−7.3
2025	Dec 31, 2025	30.4×	−5.4
2024	Dec 31, 2024	35.9×	–

Where these numbers come from

Parsed from the XBRL in TransMedics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TMDX.

Compare: TMDX vs LIVN · TMDX vs INMD · TMDX vs ITGR · TMDX vs CNMD · TMDX vs UFPT

Revenue growth28.5% · median 5.1%

Gross margin58.6% · median 43.3%

Operating margin11.9% · median 10.3%

Net margin19.9% · median 8.7%

Company	Revenue	Growth
ITGR	$1.83B	-0.3%
LIVN	$1.51B	+11.7%
CNMD	$1.37B	+1.6%
TMDX	$727.65M	+28.5%
UFPT	$649.52M	+8.6%
INMD	–	–

Company

Next earnings (est.): Feb 23, 2027, during market hours
Exchange: Nasdaq
Industry: Electromedical & Electrotherapeutic Apparatus
Fiscal year ends: December 31
Employees: 898
Held by institutions: 100.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1756262

Advertisement
300 × 250

See a number that looks wrong?

TransMedics EV/EBITDA

EV/EBITDA at the end of each year

More TransMedics figures